• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[卵巢癌患者化疗所致贫血的输血频率。关于欧洲癌症研究与治疗组织2006年修订的癌症贫血患者治疗指南的思考]

[Frequency of blood transfusions for anemia caused by chemotherapy in ovarian cancer patients. Thoughts about the guidelines modified in 2006 for the treatment of anemic cancer patients by the European Organisation for Research and Treatment of Cancer].

作者信息

Lehoczky Ottó, Pulay Tamás

机构信息

Országos Onkológiai Intézet Nogyógyászati Osztálya, Budapest.

出版信息

Orv Hetil. 2007 Nov 11;148(45):2133-7. doi: 10.1556/OH.2007.28188.

DOI:10.1556/OH.2007.28188
PMID:17984024
Abstract

INTRODUCTION

The European Organisation for Research and Treatment of Cancer distributed the modified guidelines for blood transfusions and erythropoietic drugs in the treatment of cancer anemia in the year 2006. According to this document the blood transfusions are indicated at the level of 9 g/dL of hemoglobin. Up to this year a definitive limit for applying blood transfusion in chemotherapy-induced anemia has not been determined in Hungary.

AIM

The authors evaluated their practice in the treatment of anemia with blood transfusions in ovarian cancer patients treated in 2005. In lack of international or domestic guidelines, considering also the clinical status of the patients, the authors applied blood transfusions at a hemoglobin level of 10 g/dL.

MATERIAL AND METHODS

190 epithelial ovarian cancer patients were given chemotherapy in the Gynecological Department at the National Institute of Oncology, Hungary. Selected for the patient packed red blood cell transfusion was administered if the hemoglobin has fallen below 10 g/dL, and together with it most patients (51/64 = 79,6%) were given erythropoietic drugs as well.

RESULTS

Blood transfusion was given in 64 of 190 (34%) chemotherapies patients and almost the half of these latter patients (34/64 = 53%) were transfused more than once. In 86% of patients blood transfusion was given for G2 anemia. The largest rate (16/16) of blood transfusions according to the different types of chemotherapy was done in patients receiving combined therapy with gemcitabine and carboplatin.

CONCLUSION

Chemotherapy for ovarian cancer causes severe anemia (hemoglobin level < 10 g/dL) in one third of patients. Besides blood transfusions, physicians have to pay attention to the necessity of erythropoietic drugs, as well.

摘要

引言

欧洲癌症研究与治疗组织于2006年发布了关于癌症贫血治疗中输血及促红细胞生成药物的修订指南。根据该文件,血红蛋白水平降至9 g/dL时需进行输血。直至今年,匈牙利仍未确定化疗所致贫血患者输血的明确界限。

目的

作者评估了2005年治疗的卵巢癌患者中输血治疗贫血的实践情况。由于缺乏国际或国内指南,同时考虑到患者的临床状况,作者在血红蛋白水平为10 g/dL时进行输血。

材料与方法

匈牙利国立肿瘤研究所妇科对190例上皮性卵巢癌患者进行了化疗。若血红蛋白降至10 g/dL以下,则为患者输注浓缩红细胞,并且大多数患者(51/64 = 79.6%)同时接受了促红细胞生成药物治疗。

结果

190例接受化疗的患者中有64例(34%)接受了输血,其中近一半患者(34/64 = 53%)接受了不止一次输血。86%的患者因G2级贫血接受输血。在接受吉西他滨与卡铂联合治疗的患者中,根据不同化疗类型进行输血的比例最高(16/16)。

结论

卵巢癌化疗导致三分之一的患者出现严重贫血(血红蛋白水平<10 g/dL)。除输血外,医生还必须关注促红细胞生成药物的必要性。

相似文献

1
[Frequency of blood transfusions for anemia caused by chemotherapy in ovarian cancer patients. Thoughts about the guidelines modified in 2006 for the treatment of anemic cancer patients by the European Organisation for Research and Treatment of Cancer].[卵巢癌患者化疗所致贫血的输血频率。关于欧洲癌症研究与治疗组织2006年修订的癌症贫血患者治疗指南的思考]
Orv Hetil. 2007 Nov 11;148(45):2133-7. doi: 10.1556/OH.2007.28188.
2
Anemia in cancer patients: significance, epidemiology, and current therapy.癌症患者的贫血:意义、流行病学及当前治疗方法
Oncology (Williston Park). 2002 Sep;16(9 Suppl 10):17-24.
3
Use of darbepoetin alfa in European clinical practice for the management of chemotherapy-induced anaemia in four tumour types: final data from the CHOICE study.达贝泊汀α在欧洲临床实践中用于四种肿瘤类型的化疗引起的贫血的管理:CHOICE 研究的最终数据。
Curr Med Res Opin. 2012 Jul;28(7):1089-99. doi: 10.1185/03007995.2012.698602. Epub 2012 Jun 21.
4
Identification of risk factors for requiring transfusion during front-line chemotherapy for ovarian cancer.卵巢癌一线化疗期间输血风险因素的识别
Gynecol Oncol. 2001 Jun;81(3):485-9. doi: 10.1006/gyno.2001.6185.
5
Recombinant human erythropoietin and platinum-based chemotherapy in advanced ovarian cancer.重组人促红细胞生成素与铂类化疗药物治疗晚期卵巢癌
Cancer J Sci Am. 1995 Nov-Dec;1(4):261-6.
6
Blood transfusion reduction with intravenous iron in gynecologic cancer patients receiving chemotherapy.妇科癌症患者化疗中静脉铁剂减少输血。
Gynecol Oncol. 2010 Mar;116(3):522-5. doi: 10.1016/j.ygyno.2009.12.004. Epub 2010 Jan 3.
7
Effectiveness of darbepoetin alfa versus epoetin alfa for the treatment of chemotherapy induced anemia in patients with gynecologic malignancies.达贝泊汀α与促红细胞生成素α治疗妇科恶性肿瘤患者化疗所致贫血的疗效比较
Gynecol Oncol. 2006 Jun;101(3):499-502. doi: 10.1016/j.ygyno.2005.11.027. Epub 2006 Jan 10.
8
[Questionnaire-based survey on chemotherapy-induced anemia].[基于问卷调查的化疗所致贫血研究]
Gan To Kagaku Ryoho. 2014 Apr;41(4):421-5.
9
A final analysis from the CHOICE study examining darbepoetin alfa use for chemotherapy-induced anaemia in current European clinical practice.CHOICE 研究中对当前欧洲临床实践中达贝泊汀α在化疗引起的贫血中的应用进行的最终分析。
Curr Med Res Opin. 2012 Jul;28(7):1079-87. doi: 10.1185/03007995.2012.698601. Epub 2012 Jun 21.
10
September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents.2007年9月欧洲癌症研究与治疗组织(EORTC)指南及使用促红细胞生成素治疗贫血的更新内容。
Oncologist. 2008;13 Suppl 3:33-6. doi: 10.1634/theoncologist.13-S3-33.